Twist Bioscience Hits 52-Week High After Anthropic Selects It to Validate AI Protein Designs

Twist Bioscience Corporation shares rose on Wednesday after Anthropic selected the company as an independent evaluator for protein design activities using its Claude Opus 4.8 and Mythos Preview artificial intelligence models.

Anthropic disclosed the results in an August 18 blog post. Twist Bioscience subsequently reported the development in a regulatory filing.

Twist Bioscience Tests AI-Designed Proteins

The initiative evaluated AI-designed proteins targeting 15 targets. Anthropic selected Twist Bioscience to rapidly produce these proteins at scale and test whether the designs successfully bind to their intended targets.

This work positions Twist Bioscience to play a role in independently validating proteins generated by Anthropic's AI models. Protein binding is a critical step in assessing potential designs for life sciences research and early-stage drug development.

Anthropic said it has obtained data from a multi-arm initiative using Claude Opus 4.8 and Mythos Preview.

Technical Analysis

Twist Bioscience maintains a strong uptrend. The stock trades 27.2% above its 20-day simple moving average of $108.07. It is 41.7% above the 50-day average of $96.98 and 136.3% above the 200-day average of $58.18.

The 20-day average remains above the 50-day average. Additionally, a golden cross formed in January when the 50-day average crossed above the 200-day average.

Momentum also remains positive. The moving average convergence divergence indicator sits above its signal line, while the histogram is positive.

The prior 52-week high near $126.40 may now act as support. The $108.07 level near the 20-day average represents another potential support level.

TWST price action: As of Wednesday's writing, Twist Bioscience shares were up 17.70% at $136.65. The stock is hitting a new 52-week high.